CY1120772T1 - ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ - Google Patents

ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ

Info

Publication number
CY1120772T1
CY1120772T1 CY181101073T CY181101073T CY1120772T1 CY 1120772 T1 CY1120772 T1 CY 1120772T1 CY 181101073 T CY181101073 T CY 181101073T CY 181101073 T CY181101073 T CY 181101073T CY 1120772 T1 CY1120772 T1 CY 1120772T1
Authority
CY
Cyprus
Prior art keywords
related methods
ospa fragments
mutated
mutated ospa
polypeptide
Prior art date
Application number
CY181101073T
Other languages
Greek (el)
English (en)
Inventor
Pär Comstedt
Brigitte Grohmann
Markus Hanner
Urban Lundberg
Andreas Meinke
Christoph Reinisch
Robert Schlegl
Wolfgang Schüler
Benjamin Wizel
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Publication of CY1120772T1 publication Critical patent/CY1120772T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CY181101073T 2012-07-06 2018-10-18 ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ CY1120772T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261668627P 2012-07-06 2012-07-06
US13/802,991 US8986704B2 (en) 2012-07-06 2013-03-14 Mutant fragments of OspA and methods and uses relating thereto
PCT/EP2013/064403 WO2014006226A1 (en) 2012-07-06 2013-07-08 MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO

Publications (1)

Publication Number Publication Date
CY1120772T1 true CY1120772T1 (el) 2019-12-11

Family

ID=49878705

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181101073T CY1120772T1 (el) 2012-07-06 2018-10-18 ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ

Country Status (24)

Country Link
US (9) US8986704B2 (cg-RX-API-DMAC7.html)
EP (3) EP3360568B1 (cg-RX-API-DMAC7.html)
JP (1) JP6276258B2 (cg-RX-API-DMAC7.html)
KR (2) KR102190981B1 (cg-RX-API-DMAC7.html)
CN (2) CN107602676B (cg-RX-API-DMAC7.html)
AU (2) AU2013285364B2 (cg-RX-API-DMAC7.html)
CA (1) CA2876541C (cg-RX-API-DMAC7.html)
CY (1) CY1120772T1 (cg-RX-API-DMAC7.html)
DK (1) DK2869839T3 (cg-RX-API-DMAC7.html)
EA (2) EA033007B1 (cg-RX-API-DMAC7.html)
ES (2) ES2688883T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20181689T1 (cg-RX-API-DMAC7.html)
HU (1) HUE041286T2 (cg-RX-API-DMAC7.html)
LT (1) LT2869839T (cg-RX-API-DMAC7.html)
MX (2) MX364623B (cg-RX-API-DMAC7.html)
NZ (2) NZ733026A (cg-RX-API-DMAC7.html)
PL (1) PL2869839T3 (cg-RX-API-DMAC7.html)
PT (1) PT2869839T (cg-RX-API-DMAC7.html)
RS (1) RS57847B1 (cg-RX-API-DMAC7.html)
SI (1) SI2869839T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800557T1 (cg-RX-API-DMAC7.html)
TR (1) TR201815419T4 (cg-RX-API-DMAC7.html)
WO (1) WO2014006226A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201409222B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986704B2 (en) * 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
BR112016015678B1 (pt) * 2014-01-09 2024-02-06 Valneva Austria Gmbh Polipeptídeo compreendendo um fragmento de ospa de c-terminal híbrido, seu processo de produção, seu uso, ácido nucleico, vetor, célula hospedeira, composição farmacêutica
KR102433588B1 (ko) * 2014-06-27 2022-08-19 우베 가부시키가이샤 할로겐 치환 헤테로환 화합물의 염
WO2016022958A2 (en) * 2014-08-07 2016-02-11 The Trustees Of Columbia University In The City Of New York Tick-associated virus sequences and uses thereof
WO2017108902A1 (en) * 2015-12-23 2017-06-29 Novartis Ag Oil-in-water emulsions including retinoic acid
US11345969B2 (en) 2016-02-11 2022-05-31 The Translational Genomics Research Institute Systems and methods for the detection of infectious diseases
WO2018189372A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
KR20190001421U (ko) 2019-05-26 2019-06-13 이준형 노크형 내부 수납식 칫솔
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
CN111269919B (zh) * 2020-03-19 2021-07-13 四川农业大学 玉米基因ZmLIP2及其应用
CA3174666A1 (en) 2020-04-09 2021-10-14 Robert Schlegl Improved methods of producing a lipidated protein
BR112022020438A2 (pt) * 2020-04-09 2022-11-29 Valneva Austria Gmbh Composições compreendendo três proteínas de fusão ospa para uso médico
EP4395818A4 (en) * 2021-09-02 2025-08-20 Vaxcyte Inc STABILIZATION OF ADJUVANTED VACCINE COMPOSITIONS AND THEIR USE
WO2025015077A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens
WO2025015042A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
US7008625B2 (en) * 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
PT1311540E (pt) * 2000-08-18 2008-03-20 Univ New York State Res Found Ospa de borrelia burgdorferi modificada
UA89481C2 (uk) * 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
CA2661224A1 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
SI2468300T1 (en) * 2006-09-26 2018-03-30 Infectios Disease Research Institute A vaccine composition comprising a synthetic adjuvant
TWI376385B (en) 2007-12-07 2012-11-11 Nat Health Research Institutes Production of lipidated proteins in e. coli
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
EP2470664A4 (en) 2009-08-27 2013-01-16 Synaptic Res Llc NEW PROTEIN RELEASE SYSTEM FOR GENERATING INDUCED PLURIPOTENTAL STEM CELLS OR TISSUE-SPECIFIC CELLS
EP2569008B1 (en) 2010-05-14 2019-12-25 Baxalta Incorporated Ospa chimeras and use thereof in vaccines
DK2753352T4 (da) 2010-09-03 2022-09-12 Valneva Austria Gmbh Isoleret polypeptid af toxin a og toxin b proteinerne fra c. difficile og anvendelser deraf
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
US9925257B2 (en) 2011-09-23 2018-03-27 Forsyth Dental Infirmary For Children Vaccine and therapeutic delivery system
EP2788200B1 (en) 2011-12-06 2018-07-04 Mubea Carbo Tech GmbH Wheel made out of fiber reinforced material and procedure to make an according wheel
PL3106176T3 (pl) 2011-12-06 2018-03-30 Valneva Austria Gmbh Związki glinu do stosowania w terapeutykach i szczepionkach
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
BR112016015678B1 (pt) 2014-01-09 2024-02-06 Valneva Austria Gmbh Polipeptídeo compreendendo um fragmento de ospa de c-terminal híbrido, seu processo de produção, seu uso, ácido nucleico, vetor, célula hospedeira, composição farmacêutica
CZ2014320A3 (cs) 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
WO2017096486A1 (en) 2015-12-10 2017-06-15 National Research Council Of Canada Lipidated streptococcus pneumoniae antigen compositions, methods of preparation and use
WO2018189372A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
WO2019092002A1 (en) 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
BR112021021637A2 (pt) 2019-05-20 2021-12-21 Valneva Se Vacina de subunidade para tratamento ou prevenção de uma infecção do trato respiratório
JP7116256B1 (ja) 2020-04-02 2022-08-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体および抗原結合断片
CA3174666A1 (en) 2020-04-09 2021-10-14 Robert Schlegl Improved methods of producing a lipidated protein

Also Published As

Publication number Publication date
HK1207982A1 (en) 2016-02-19
JP2015522270A (ja) 2015-08-06
KR20150036191A (ko) 2015-04-07
CN104487084B (zh) 2017-09-22
CN107602676B (zh) 2021-06-04
US20140010835A1 (en) 2014-01-09
ES2688883T3 (es) 2018-11-07
ES2800873T3 (es) 2021-01-04
SMT201800557T1 (it) 2018-11-09
NZ703597A (en) 2017-06-30
CA2876541C (en) 2022-03-01
US20170107263A1 (en) 2017-04-20
US20220185851A1 (en) 2022-06-16
CN104487084A (zh) 2015-04-01
HUE041286T2 (hu) 2019-05-28
DK2869839T3 (en) 2018-10-15
US11466058B2 (en) 2022-10-11
MX2015000013A (es) 2015-06-04
US20230295245A1 (en) 2023-09-21
WO2014006226A1 (en) 2014-01-09
TR201815419T4 (tr) 2018-11-21
LT2869839T (lt) 2018-11-12
US20150232517A1 (en) 2015-08-20
HK1257893A1 (en) 2019-11-01
KR102393038B1 (ko) 2022-04-29
US20180327460A1 (en) 2018-11-15
EA033007B1 (ru) 2019-08-30
CA2876541A1 (en) 2014-01-09
SI2869839T1 (sl) 2018-11-30
EP3689372A1 (en) 2020-08-05
MX391136B (es) 2025-03-21
KR102190981B1 (ko) 2020-12-15
RS57847B1 (sr) 2018-12-31
US10544194B2 (en) 2020-01-28
AU2017218974A1 (en) 2017-09-07
US9926343B2 (en) 2018-03-27
KR20200141096A (ko) 2020-12-17
PL2869839T3 (pl) 2018-12-31
AU2013285364B2 (en) 2017-06-15
EA201991059A1 (ru) 2020-01-31
US12195501B2 (en) 2025-01-14
CN107602676A (zh) 2018-01-19
EP3360568A1 (en) 2018-08-15
US11208439B2 (en) 2021-12-28
PT2869839T (pt) 2018-11-12
US20170101446A1 (en) 2017-04-13
ZA201409222B (en) 2016-08-31
US20150250865A1 (en) 2015-09-10
HK1248244A1 (zh) 2018-10-12
HK1209370A1 (en) 2016-04-01
EP2869839A1 (en) 2015-05-13
AU2017218974B2 (en) 2019-05-30
US8986704B2 (en) 2015-03-24
HRP20181689T1 (hr) 2018-12-28
JP6276258B2 (ja) 2018-02-07
AU2017218974C1 (en) 2020-02-20
NZ733026A (en) 2019-09-27
AU2013285364A1 (en) 2015-01-29
US20200239525A1 (en) 2020-07-30
EP2869839B1 (en) 2018-09-05
EP3360568B1 (en) 2020-03-04
MX364623B (es) 2019-05-03
EA201590162A1 (ru) 2015-06-30

Similar Documents

Publication Publication Date Title
CY1120772T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
CY1121734T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
CY1121934T1 (el) Αντισωματα anti-fcrn
CY1125144T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης
CY1123563T1 (el) Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων
MX361728B (es) Ácido nucleico que comprende o codifica un tallo-bucle de histona y una secuencia poli(a) o una señal de poliadenilación para incrementar la expresión de un antígeno tumoral codificado.
CY1121455T1 (el) Πολυπεπτιδια τα οποια δεσμευονται σε ανθρωπινη c5 συμπληρωματικου
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
CY1121964T1 (el) Αντισωματα εναντιον toy csf-1r
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
MD4716B1 (ro) Anticorpi anti-LAG3 şi fragmente de legare a antigenului
EP4620530A3 (en) Neutralizing antibodies to gp120 and their use
BR112015003757A2 (pt) anticorpos e vacinas para uso no tratamento de cânceres de ror1 e inibição de metástase
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
EA202090275A3 (ru) Антитела против с5 с улучшенными фармакокинетическими характеристиками
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
NZ730763A (en) Methods of treating a tauopathy
EA201291195A1 (ru) Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1
MX385872B (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
EA201690159A1 (ru) Способы и композиции для лечения рака
UA117045C2 (uk) Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування
NZ745327A (en) Whole-cell cancer vaccines and methods for selection thereof
MX360085B (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.